An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

Completed · Phase 2 · Has a placebo group

Conditions studied: Resistant Hypertension

In brief

The purpose of this 20-week randomized double-blind study in patients with resistant hypertension (rHTN) is to evaluate the efficacy, safety, and tolerability, of different doses of XXB750 administered as subcutaneous (SC) injections, compared to placebo. Since all study participants will be patients with rHTN, all study treatments will be given on top of maximally tolerated background antihypertensive therapy recommended by international guidelines for treatment of HTN (i.e., a thiazide or a thiazide-like diuretic, an angiotensin converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB), and a long-acting dihydropyridine calcium channel blocker (CCB).

Key facts

Study ID

NCT05562934

Run by

Novartis Pharmaceuticals

People needed

189

Starts

2022-11-08

Expected to finish

2024-08-27

Last updated by the study team

2026-01-12

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female participants who are ≥ 18 years old.
• Signed informed consent prior to participation in the study.
• Apparent rHTN at screening (Visit 1) defined as uncontrolled BP with an office msSBP ≥ 140 mmHg despite treatment with stable (i.e., unchanged for ≥4 weeks), optimal or maximally tolerated doses of three or four antihypertensive drugs of different classes, including an ACEI/ARB, a long-acting dihydropyridine CCB, and a thiazide or thiazide-like diuretic. Participant with documented intolerance to any doses of CCBs may be eligible if receiving another class of antihypertensive medication at an optimal or maximally tolerated dose (referred to as triple background antihypertensive therapy. An optimal dose is defined as the highest dose taking in to account participant's documented comorbidities and tolerability per investigator's clinical judgment.
• Mean 24hr SBP ≥135 mmHg (measured by ABPM) at the end-of Run-in-Visit (Visit 30) on treatment with optimal or maximally tolerated doses of an ACEI/ARB, a long-acting dihydropyridine CCB (or a suitable alternative in case of intolerance per inclusion criterion above), and a thiazide or thiazide-like diuretic.

You may not qualify if…

• Subjects with the following blood pressures at the specified time points are not eligible to participate in the study:
• Office msSBP <140 mmHg at Visit 20 OR
• Office msSBP ≥180 mmHg or office msDBP ≥110 mmHg at the end-of-run-in visit (Visit 30) OR
• 24h mean SBP >170 mmHg or 24h mean DBP >105mmHg measured by ABPM at the end of the run-in (Visit 30).
• Known history of secondary hypertension (moderate-to-severe obstructive sleep apnea without receiving CPAP therapy (either face mask or nasal device), renovascular hypertension, primary aldosteronism, pheochromocytoma, Cushing syndrome, aortic coarctation or other cause of secondary hypertension).
• Estimated GFR <30 mL/min/1.73m2 using CKD-Epi equation at screening (Visit 1) or at end-of-run-in visit (Visit 30).
• Serum potassium >5.0 mmol/L (or equivalent plasma potassium value) at screening or end-of-run-in visit (Visit 30).
• Current therapy with a mineralocorticoid receptor antagonist (MRA) or sacubitril/valsartan or received an MRA or sacubitril/valsartan within the 4 weeks prior to screening.
• Type I diabetes mellitus or uncontrolled Type II diabetes (defined as a plasma HbA1c ≥9%)
• Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), high-grade AV block (e.g., Mobitz type II and third-degree AV block in absence of a pacemaker) within 6 months of screening according to investigator's judgement.
• Chronic non-paroxysmal atrial fibrillation.
• Acute myocardial infarction (AMI) or unstable angina, or any history of ischemic or hemorrhagic stroke within 12 months of screening; or any percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) within 12 months of screening
• History of a renal denervation procedure.
• Mid-arm circumference ≥44 cm. The cuff should snugly fit on the arm with out the margins of cuff overhanging arm musculature.
• Patients with history of hospitalisation for hypertensive emergencies characterised by severe hypertension (usually grade 3) associated with funduscopic changes (flame haemorrhages and/or papilloedema), microangiopathy, disseminated intravascular coagulation, encephalopathy, acute aortic dissection, acute myocardial ischaemia, or acute heart failure any time prior to screening or hospitalisation for non-emergent/non-urgent uncontrolled hypertension without target organ damage within 3 months prior to screening
• Receiving more than 4 antihypertensive medications.
• Night shift workers.
• History of presence of any other disease where the life expectancy is less than 3 years.
• History of malignancy of any organ system (other than localized basal or squamous cell carcinoma of the skin or localized prostate cancer), treated or untreated, within the past 3 years, regardless of whether there is evidence of local recurrence or metastases.
• Evidence of hepatic disease as determined by any one of the following: SGOT (AST) or SGPT (ALT) values exceeding 3x the upper limit of normal (ULN), or bilirubin >1.5 mg/dl at Visit 1.
• Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
• History of drug abuse or alcohol dependency.
• Lacking the ability to comprehend or follow instructions, or for any reason in the opinion of the investigator, a participant that would be unlikely or unable to comply with study protocol.
• Concurrent enrollment in any other investigational drug or device trial (participation in non-interventional registries is acceptable).
• Requiring prolonged/regular use of NSAIDs except for prophylactic use of low dose aspirin up to 325 mg QD or other prohibited medications during of the study (i.e., required use for longer than 1 week).

Where it is running

• Parkway Medical Center — Birmingham, Alabama, United States
• Clinical Trials Research Sacramento — Sacramento, California, United States
• Orange County Research Center — Tustin, California, United States
• Jacksonville Center for Clinical Research — Jacksonville, Florida, United States
• Canvas Clinical Research — Lake Worth, Florida, United States
• Inpatient Research Clinical LLC — Miami Lakes, Florida, United States
• Cardiology Partners Clinical Research Institute — Wellington, Florida, United States
• American Clinical Trials — Acworth, Georgia, United States
• Alliance for Multispecialty Resrch — Wichita, Kansas, United States
• Anderson Medical Research — Ft. Washington, Maryland, United States
• Capitol Cardiology Associates — Lanham, Maryland, United States
• MD Medical Research — Oxon Hill, Maryland, United States
• NexGen Research — Lima, Ohio, United States
• The Research Center of the Upstate — Greenville, South Carolina, United States
• Tennessee Center For Clinical Trials — Tullahoma, Tennessee, United States
• Manassas Clinical Research Center — Manassas, Virginia, United States
• Dominion Medical Associates — Richmond, Virginia, United States
• Novartis Investigative Site — Adelaide, South Australia, Australia
• Novartis Investigative Site — Perth, Western Australia, Australia
• Novartis Investigative Site — Graz, Austria
• Novartis Investigative Site — Vienna, Austria
• Novartis Investigative Site — Pleven, Bulgaria
• Novartis Investigative Site — Sofia, Bulgaria
• Novartis Investigative Site — Sofia, Bulgaria
• Pinnacle Research Group Llc — Anniston, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.